Argot

Hi

[Craig o @c_olvrin]

@aob4227O @braintumorshare Yesterday in Japan the MHLW Panel Backs Japan’s 1st Oncolytic Virus for Conditional Approval!!! #G47∆ #Teserpaturev

[Argot @aob4227O]

@c_olvrin @BeaconIntel Thank you!

[Argot @aob4227O]

I am not sure even after reading this

[Argot @aob4227O]

Shouldn’t it be juncture?

[Elon Musk @elonmusk]

@davelee @Tesla A remarkable junction in history

[Argot @aob4227O]

@GuptaBioDD @tradingview Are you that bullish about cmv as a target that you think it could really be soc? Are they even in phase iii? (Sorry, layperson here)

[Argot @aob4227O]

@tomfgoodwin Also they made everyone think advertising had to be as science-based as tech, which just forced a lot of people9 to adopt the language of science without adopting the substance (which, in an ad context, was never fully possible anyway).

[Argot @aob4227O]

@tomfgoodwin The “idyllic future” they promised—perfectly personalized ads—was never that plausible with existing tech. We won’t get personalized ads before we have personalized, tech-informed art. What’s happened is that art, too, seems to be less and less relevant.

[Argot @aob4227O]

@NicholasBlondin @NeuroOnc Are there promising trials? I wonder if it would be possible to enroll in simultaneously in a “diagnostic” trial and a “treatment” trial. We are already enrolled in a promising “treatment” trial but would appreciate trying something that circumvents the need for/issues with MRIs.

[Anastasia Golovashkina @golovashkina]

In June 2019, I learned I had a billiard ball-sized tumor in my brain—one biopsy would soon confirm to be glioblastoma, the most aggressive brain cancer.

Today in @ElleMagazine, I'm sharing my story—and asking @JoeBiden to resume his cancer moonshot. https://t.co/2b8Q89d0uB

[Argot @aob4227O]

@platten_michael @wick_wolfgang @HdNeurooncology @uniklinik_hd @NCT_HD @DKFZ Does the success here (93% response rate!) potentially have any broader implications for patients with IDH wildtype? Is there someone at the lab a layperson can write to to understand the meaning of the study better?

[Argot @aob4227O]

@braintumorshare Is there any more news on teserpaturev? Can’t find updates in English.

(If you answer in Japanese, I can simply use the twitter translate function 👍)

[Argot @aob4227O]

@justinkeister5 @The_PennyQueen Is the patient population to account for some of the mOS and X-year survival benefit? Dcvax seems to have a significantly larger portion of methylated patients. It would be good to see the 1, 2, 3-year survival benefit by methylation status too.

[Argot @aob4227O]

@justinkeister5 @KnowWhatYouHold Do you have any opinion on the DC vaccines that target CMV?

[Argot @aob4227O]

@justinkeister5 @KnowWhatYouHold I am kind of a layperson in this space, but isn’t the CD200 trial promising in this regard?

[Will Grundy @WillGTweeting]

The fact that Panic! At The Tesco hasn't become a #coronavirus stockpiling headline quite yet is far beyond me.

[Argot @aob4227O]

@StenderWorld Sorry, here's the correct article. The IPA report it refers to is worth checking out, but I don't have it handy: https://t.co/Wi6RgbxOvr

[Argot @aob4227O]

@StenderWorld It mentions that, like I said, the industry has been rewarding this behavior: "The report pointed to the industry’s obsession with awards, with some 80%of this years Cannes Lions Awards being handed out to one-off activations, as the reason for the decline."

[Jason Lee @the_jason_lee]

@seldo Read through https://t.co/QKQmrhnoeu and you'll find that actual data scientists have been complaining about this for years! It is still an issue too. Companies create roles for technical folks and don't really know what the new person is supposed to do.